Expert Review of Hematology最新文献_第2页

Anemia and its predictors among patients on hemodialysis, at Felege Hiote Referral Hospital, Northwest Ethiopia, 2022: a retrospective cohort study.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-29 DOI: 10.1080/17474086.2025.2458272

Mihretie Gedfew, Addisu Getie

{"title":"Anemia and its predictors among patients on hemodialysis, at Felege Hiote Referral Hospital, Northwest Ethiopia, 2022: a retrospective cohort study.","authors":"Mihretie Gedfew, Addisu Getie","doi":"10.1080/17474086.2025.2458272","DOIUrl":"10.1080/17474086.2025.2458272","url":null,"abstract":"Background: Anemia is a critical complication among hemodialysis patients, often leading to poor outcomes. This study aimed to assess anemia prevalence and identify predictors among hemodialysis patients at Felege Hiote Referral Hospital, Northwest Ethiopia, in 2022.Research design and methods: A retrospective cohort study analyzed 410 hemodialysis patients from January 2018 to February 2022. Data was collected from medical records, entered using Epi-data Version 4.1, and analyzed with STATA Version 14. Kaplan-Meier survival curves assessed survival time, while Cox regression identified anemia predictors.Results: Of 410 patients, 66 (16.1%) developed anemia, with an incidence rate of 7.9 per 100 person-years (95% CI: 3.1-13.5). Significant predictors included female sex (IRR: 1.5, p = 0.04), rural residence (IRR: 2.5, p = 0.01), low body mass index (IRR: 1.6, p = 0.02), and congestive heart failure (IRR: 6.9, p = 0.02).Conclusions: Anemia prevalence among hemodialysis patients is high, with key predictors including gender, residence, body mass index, and comorbidities. Interventions targeting these factors, especially in rural areas, could reduce anemia incidence. Study limitations include single-center data, incomplete variables, and lack of causality.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"143-153"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet indices in preeclampsia: comparative analysis with normotensive pregnant women.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-30 DOI: 10.1080/17474086.2025.2458262

Hamza Tariq, Muhammad Hamza Khan, Fnu Poombal, Muhammad Saad Khan, Minahil Mateen Ahmad, Mehreen Khalid, Umera Saleem

{"title":"Platelet indices in preeclampsia: comparative analysis with normotensive pregnant women.","authors":"Hamza Tariq, Muhammad Hamza Khan, Fnu Poombal, Muhammad Saad Khan, Minahil Mateen Ahmad, Mehreen Khalid, Umera Saleem","doi":"10.1080/17474086.2025.2458262","DOIUrl":"10.1080/17474086.2025.2458262","url":null,"abstract":"Background: To compare platelet count (PC), mean platelet volume (MPV), and platelet distribution width (PDW) between women with preeclampsia (PE) and normotensive pregnant women, and evaluate their effectiveness as predictors of PE.Research design and methods: This cross-sectional study at Nishtar Hospital, Multan, included 141 women: 74 normotensive and 67 preeclamptic. Data was collected using an automated hematology analyzer and analyzed with SPSS version 26 and ROC curves.Results: Mean age was 27.45 ± 5.18 years for cases and 28.41 ± 5.28 years for controls (p = 0.280). Gestational age was lower in the preeclamptic group (31.97 ± 4.07 weeks) compared to controls (33.92 ± 3.30 weeks) (p = 0.002). Blood pressures were higher in preeclamptic women (p < 0.001). Platelet count was lower in preeclamptic women (183.42 ± 95.69) vs. controls (256.42 ± 77.98) (p < 0.001). MPV (10.98 ± 1.55 vs. 9.79 ± 1.59, p < 0.001) and PDW (16.82 ± 5.70vs. 14.20 ± 2.40, p < 0.001) were higher in preeclamptic women. ROC analysis showed PDW had an AUC of 0.73 and MPV an AUC of 0.71.Conclusions: PDW and MPV are significantly altered in preeclamptic women and can aid in early detection, potentially enhancing management.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"135-142"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sports practice should be supported in people with severe hemophilia, but patient counseling and tailoring prophylactic treatment with clotting factors and non-replacement therapy is essential.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1080/17474086.2025.2459271

Emerito Carlos Rodriguez-Merchan, Hortensia De la Corte-Rodriguez

{"title":"Sports practice should be supported in people with severe hemophilia, but patient counseling and tailoring prophylactic treatment with clotting factors and non-replacement therapy is essential.","authors":"Emerito Carlos Rodriguez-Merchan, Hortensia De la Corte-Rodriguez","doi":"10.1080/17474086.2025.2459271","DOIUrl":"10.1080/17474086.2025.2459271","url":null,"abstract":"Introduction: This article discusses the current role of sports practice in people with hemophilia (PWH).Areas covered: On 11 January 2025, a bibliographic search was carried out in PubMed using 'hemophilia sports' as keywords. A total of 411 articles were found, of which only 22 were finally analyzed because they were directly related to the title of this article (inclusion criterion). The remaining 389 were eliminated because they were not directly related to the title of the article (exclusion criterion). It was found that sports activity is essential for patients with severe hemophilia to maintain joints' range of motion, diminish joint bleeding, enhance muscle mass and strength, improve proprioception, muscular trophism and bone mineral density, and avert secondary joint degeneration. PWH with factor levels < 10% during sports had a bleeding risk of 41% versus 20% in those with higher factor levels (>10%).Expert opinion: Prophylaxis therapy can permit patients with severe hemophilia to participate in vigorous activities or high-impact sports. Moreover, such activities or sports have a positive effect on patient's psychosocial health. Therefore, sports practice should be supported in people with severe hemophilia but patient counseling and tailoring prophylaxis therapy with clotting factors and non-replacement therapy is essential.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"123-134"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The future of siRNA-mediated approaches to treat von Willebrand disease.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-29 DOI: 10.1080/17474086.2025.2459259

Noa A Linthorst, Bart J M van Vlijmen, Jeroen C J Eikenboom

{"title":"The future of siRNA-mediated approaches to treat von Willebrand disease.","authors":"Noa A Linthorst, Bart J M van Vlijmen, Jeroen C J Eikenboom","doi":"10.1080/17474086.2025.2459259","DOIUrl":"10.1080/17474086.2025.2459259","url":null,"abstract":"Introduction: The clinical management of the inherited bleeding disorder von Willebrand disease (VWD) focuses on normalizing circulating levels of von Willebrand factor (VWF) and factor VIII (FVIII) to prevent or control bleeding events. The heterogeneous nature of VWD, however, complicates effective disease management and development of universal treatment guidelines.Areas covered: The current treatment modalities of VWD and their limitations are described and why this prompts the development of new treatment approaches. In particular, RNA-based therapeutics have gained significant interest because of their ability to reversibly alter gene expression with long-term efficacy. In the field of VWD, small-interfering RNAs (siRNAs) have been explored through various strategies to improve disease phenotypes. These different approaches are discussed as well as their potential impact on reshaping the future therapeutic landscape.Expert opinion: Current treatments for VWD often require frequent intravenous administration of VWF concentrates or desmopressin, with only short-term benefits. Moreover, remaining circulating mutant VWF can cause detrimental effects. Allele-selective siRNA-based therapies could provide more reliable and long-term disease correction by specifically targeting mutant VWF. This approach could be applied to a large part of the population aligning with the growing emphasis on personalized treatment and patient-centered care in VWD management.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"109-122"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 associated thrombotic thrombocytopenic purpura: a case report and review of the literature.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 DOI: 10.1080/17474086.2025.2459260

Elie Bou Sanayeh, Layal Al Mahmasani, Zaid Khamis, Salim Barakat, Carolla El Chamieh, Georges Khattar, Alexandre Matar, Firas Kreidieh, Sally Temraz

{"title":"COVID-19 associated thrombotic thrombocytopenic purpura: a case report and review of the literature.","authors":"Elie Bou Sanayeh, Layal Al Mahmasani, Zaid Khamis, Salim Barakat, Carolla El Chamieh, Georges Khattar, Alexandre Matar, Firas Kreidieh, Sally Temraz","doi":"10.1080/17474086.2025.2459260","DOIUrl":"10.1080/17474086.2025.2459260","url":null,"abstract":"Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening complication whose association with COVID-19 is controversial. Understanding this connection is essential due to its significant impact on patient outcomes, and timely diagnosis and intervention are critical in managing this condition effectively.Areas covered: This paper presents a case of TTP triggered by COVID-19 infection in a 48-year-old female. Additionally, a comprehensive literature review was conducted using PubMed and Google Scholar databases, from inception through August 2024, to identify all published cases of COVID-19-associated TTP. The literature search focused on adult cases of TTP secondary to COVID-19 infection, highlighting the treatments used and patient outcomes.Expert opinion: In this report, we highlight the importance of recognizing TTP as a possible complication of COVID-19. While the standard treatment for TTP - plasma exchange and corticosteroids - remains the primary approach, we note that COVID-19-related cases exhibit a high risk of early relapse, as seen in our patient. The literature review suggests that TTP triggered by COVID-19 may have unique characteristics, such as a persistent low ADAMTS13 activity and increased relapse rates. Larger studies are necessary to develop optimal treatment guidelines and understand whether the presence of COVID-19 alters the typical clinical course of TTP.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-15"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring shared pathogenesis of multiple myeloma and osteoporosis via bioinformatic analysis.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-02-14 DOI: 10.1080/17474086.2025.2465456

Yajie Wang, Chengdi Liu, Kegong Tang, Jiyun Zhang, Xinran Liu, Yiming Ma, Xiaofei Li

{"title":"Exploring shared pathogenesis of multiple myeloma and osteoporosis via bioinformatic analysis.","authors":"Yajie Wang, Chengdi Liu, Kegong Tang, Jiyun Zhang, Xinran Liu, Yiming Ma, Xiaofei Li","doi":"10.1080/17474086.2025.2465456","DOIUrl":"10.1080/17474086.2025.2465456","url":null,"abstract":"Background: The purpose of this study is to explore the common differentially expressed genes (DEGs) between multiple myeloma (MM) and osteoporosis and the associated molecular mechanisms.Research design and methods: We obtained the overlapping DEGs between MM and osteoporosis with the GEO2R online tool. Then, the DEGs were clustered on the MetaCore website to identify the biological process and pathway. In addition, the STRING database and Cytoscape were used to construct the protein-protein interaction (PPI) network and identify hub genes. Finally, miRNA-gene and transcriptional factor (TF)-gene interaction networks were constructed.Results: A total of 252 genes were identified as DEGs in the overlapping two datasets. Functional analysis emphasizes the crucial role of the cell cycle in these two diseases. 10 hub genes were identified using cytoHubba, including CCNA2, ASPM, MKI67, FN1, FEN1, STAT1, DEPDC1, ITGB8, DYNC2LI1, HBEGF. In addition, according to the miRNA-gene and TF-gene interaction networks, part of TFs (RELA, TP53), and miRNAs (miR-26b-5p, miR-192-5p) may be identified as key regulators in MM and osteoporosis at the same time.Conclusions: The present study reveals the common pathogenesis of MM and osteoporosis. These shared pathways may provide new targets for further mechanistic studies of the pathogenesis and treatment of MM and osteoporosis.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"167-176"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study.

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1080/17474086.2025.2459251

Mingyi Yang, Yani Su, Pengfei Wen, Jiale Xie, Xianjie Wan, Ke Xu, Wensen Jing, Zhi Yang, Lin Liu, Peng Xu

{"title":"Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study.","authors":"Mingyi Yang, Yani Su, Pengfei Wen, Jiale Xie, Xianjie Wan, Ke Xu, Wensen Jing, Zhi Yang, Lin Liu, Peng Xu","doi":"10.1080/17474086.2025.2459251","DOIUrl":"10.1080/17474086.2025.2459251","url":null,"abstract":"Objective: Deep vein thrombosis (DVT) is a known complication of fractures. This study aimed to explore the genetic causal relationship between DVT and fracture sites.Research design and methods: The exposures analyzed in this study included fracture of femur (FFE), fracture of lower leg, including ankle (FLLA), fracture of shoulder and upper arm (FSUA), fracture of forearm (FFO), fracture of rib, sternum and thoracic spine (FRSTS) and fracture of lumbar spine and pelvis (FLSP). DVT as the outcome. A two-sample Mendelian randomization (MR) approach was employed to investigate the genetic causal relationship, and a series of sensitivity analyses were conducted.Results: The findings indicated no genetic causal relationship between FFE (p = 0.569, OR 95% CI = 1.001 [0.998-1.003]), FLLA (p = 0.371, OR 95% CI = 0.999 [0.995-1.002]), FSUA (p = 0.871, OR 95% CI = 1.000 [0.998-1.002]), FFO (p = 0.281, OR 95% CI = 1.001 [0.999-1.002]), FRSTS (p = 0.346, OR 95% CI = 0.999 [0.996-1.001]) or FLSP (p = 0.759, OR 95% CI = 1.000 [0.999-1.002]) and DVT. Sensitivity analyses reinforced the robustness.Conclusions: This study indicate that no genetic causal relationship exists between DVT and fracture site, the observed association may be attributable to non-genetic factors.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"155-165"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could targeted gene insertion of factor 9 be a potential durable treatment for Hemophilia B?

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1080/17474086.2025.2459253

Giancarlo Castaman, Mirko Pinotti

引用次数: 0

Challenges and emerging therapeutic strategies for TP53-mutated acute myeloid leukemia: still disappointing findings? tp53突变急性髓性白血病的挑战和新兴治疗策略：仍然令人失望的发现？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI: 10.1080/17474086.2024.2438241

Matteo Molica

引用次数: 0

Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review. 描述用inotuzumab ozogamicin治疗复发/难治性急性淋巴细胞白血病的理想患者：系统文献综述

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-01-14 DOI: 10.1080/17474086.2025.2450223

David I Marks, Ryan D Cassaday, Josep-Maria Ribera, Andre C Schuh, Jae H Park, Sabina Chiaretti, Matthias Stelljes

{"title":"Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review.","authors":"David I Marks, Ryan D Cassaday, Josep-Maria Ribera, Andre C Schuh, Jae H Park, Sabina Chiaretti, Matthias Stelljes","doi":"10.1080/17474086.2025.2450223","DOIUrl":"10.1080/17474086.2025.2450223","url":null,"abstract":"Introduction: Inotuzumab ozogamicin (InO) is indicated for the treatment of adults with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). This systematic literature review (CRD42022330496) assessed outcomes by baseline characteristics for patients with R/R ALL treated with InO to identify which patients may benefit most.Methods: In adherence with PRISMA guidelines, searches were run in Embase and MEDLINE. Inclusion criteria were real-world evidence, observational studies, and phase 2-4 trials. The Cochrane Risk of Bias tool and Newcastle-Ottawa instrument assessed quality.Results: 34 publications were included; 11 described the phase 3 INO-VATE trial. Patients treated with InO who were CD22-positive, in first salvage, and eligible for subsequent hematopoietic stem cell transplant (HSCT) had improved outcomes. Reduced incidence of veno-occlusive disease was observed in patients with normal transaminase levels and bilirubin, no prior liver disease, and who did not receive dual alkylators.Conclusions: The ideal patient for InO treatment has CD22-positive disease (≥20% leukemic blasts), normal liver function, no history of liver disease, is in first salvage, has not previously received HSCT, prefers outpatient treatment, or has high disease burden. Limitations included potentially missing publications that were non-English, not identified in the searches, or available after the date the searches were conducted.Registration: This systematic review was registered on the Prospective Register of Systematic Reviews (PROSPERO), registration number: CRD42022330496.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"91-103"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0